Brought to you by:
Stryker completes acquisition of Inari Medical
Stryker announced today that it has completed the acquisition of Inari Medical. A press release notes that the addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing venous thromboembolism (VTE) segment. “The acquisition of Inari…
VenaCore device offers long-awaited interventional solution for challenging venous occlusions
This advertorial is sponsored by Inari Medical. Despite the recent growth in mechanical thrombectomy devices for acute deep vein thrombosis (DVT), interventional options for wall adherent venous obstruction are extremely limited. Residual venous obstruction after medical or interventional therapy for…
Inari Medical updates ClotTriever XL IFU amid FDA recall notice
The Food and Drug Administration (FDA) has issued a Class I recall—the most serious type—for Inari Medical‘s ClotTriever XL, 30mm device due to reports of patient injury, and death from device entrapment and pulmonary emboli (PE). The device remains on…
Tackling DVT head on: Single-session, wall-to-wall thrombus removal with the ClotTriever BOLD
This advertorial is sponsored by Inari Medical. Several years ago, when Nicolas Mouawad, MD, division chief of vascular surgery at McLaren Health in Bay City, Michigan, was confronted with an emergency case of deep vein thrombosis (DVT) in which the…
Mechanical thrombectomy demonstrates superior outcomes to anticoagulation in DVT patients, analysis of RCT and registry data shows
Mechanical thrombectomy using the ClotTriever device (Inari Medical) for iliofemoral deep vein thrombosis (DVT) was found to be “associated with significantly” lower Villalta scores and a lower incidence of post-thrombotic syndrome (PTS) out to 12 months compared with treatment using anticoagulation,…
One-year CLOUT data demonstrate low rate of PTS following treatment with ClotTriever
David Dexter (Sentara Vascular Specialists, Norfolk, USA) shared one-year data from the CLOUT registry this week at The VEINS 2023 (28–30 October, Las Vegas, USA). Long-term, prospective outcome data after mechanical thrombectomy for deep vein thrombosis (DVT) are lacking. The…
First patient enrolled in DEFIANCE trial of the ClotTriever system in DVT
Inari Medical announced that the first patient has been enrolled in DEFIANCE, a prospective randomized controlled trial (RCT) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only. The trial is…
Mechanical thrombectomy for DVT: Randomized data needed to boost growing evidence base
Two datasets presented during the late-breaking clinical trials session at The VEINS (Venous Endovascular Interventional Strategies) 2022 (Oct. 30–31) in Las Vegas—the latest results from CLOUT and a propensity score-matched analysis of CLOUT versus ATTRACT—bolster the evidence base for mechanical…
Clinical outcomes of the ClotTriever system in DVT set to be evaluated in RCT
Inari Medical has announced planned enrollment of the DEFIANCE randomized controlled trial (RCT), which is designed to compare the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only. The trial will enroll 300 patients…
AVF 2022: Six-month CLOUT data indicate ClotTriever can effectively remove full spectrum of thrombus
Six-month outcomes from the ongoing CLOUT registry demonstrate the “safety and efficacy” of the ClotTriever thrombectomy system in a real-world deep vein thrombosis (DVT) population regardless of clot chronicity level, the 2022 annual meeting of the American Venous Forum (AVF)…